|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both univariate and multiple linear regression analysis indicated that only <i>CYP2D6*10</i> allele was associated with higher Cpss (<i>p</i>-value =0.029 and B =0.478, <i>p</i>-value =0.032, respectively) that might influence the clinical outcomes of donepezil. ie, TMSE (<i>p</i>-value =0.010 and B =4.527, <i>p</i>-value =0.001) and ΔTMSE (<i>p</i>-value =0.023 and B =4.107, <i>p</i>-value =0.002), especially in patients with AD.
|
31564952 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP2D6*10 carriers responded better to ChEIs and resulted in better improvement in Alzheimer's Disease Assessment Scale-Cognitive subscale (<i>P</i> = .027) and Mini-Mental State Examination (<i>P</i> = .012).
|
31064198 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genotyping of clinically relevant <i>CYP2D6</i> alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy.
|
31178724 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.
|
30357449 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
|
30843495 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
|
31195002 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results are consistent with the relatively few other large, population-based studies conducted to date that have not observed an increased risk of adverse BC outcomes associated with CYP2D6 inhibition.
|
30542984 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
|
29135105 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specifically, the potential of the CYP2D6 to be inhibited by drug-induced phenoconversion was associated with a higher severity of depression (<i>p</i> < .05).
|
31750687 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The predictors of delayed remission included unemployment (P = .004), severe medical comorbidity (P < .0001), severe baseline depression (P < .0001), more than 4 dysthymic symptoms (P = .005), more than 9 posttraumatic stress symptoms (P = .005), and serotonin receptor 1A (P = .006) and cytochrome P450 2D6 (P = .002 for C/T and P = .0004 for T/T) genetic variants.
|
29178685 |
2019 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
|
31100205 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The predictors of delayed remission included unemployment (P = .004), severe medical comorbidity (P < .0001), severe baseline depression (P < .0001), more than 4 dysthymic symptoms (P = .005), more than 9 posttraumatic stress symptoms (P = .005), and serotonin receptor 1A (P = .006) and cytochrome P450 2D6 (P = .002 for C/T and P = .0004 for T/T) genetic variants.
|
29178685 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specifically, the potential of the CYP2D6 to be inhibited by drug-induced phenoconversion was associated with a higher severity of depression (<i>p</i> < .05).
|
31750687 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we show that the mitochondrially targeted CYP2D6 can efficiently catalyze MPTP-mimicking compounds, <i>i.e.</i> 2-methyl-1,2,3,4-tetrahydroisoquinoline, 2-methyl-1,2,3,4-tetrahydro-β-carboline, and 9-methyl-norharmon, suspected to induce PD in humans.
|
31113867 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, an elegant roadmap was laid out a year ago by Karolina Kauppi and colleagues wherein they combined a data set for schizophrenia risk genes and another set of genes associated with antipsychotic drug targets.<sup>3</sup> Using this "network biology" approach, they identified four schizophrenia risk genes that were also antipsychotic drug targets (GRM3, DRD2, CHRM4, and CYP2D6); they also found several molecular targets that are not currently connected to antipsychotic drug treatment, providing researchers with some potential targets for novel therapeutics.<sup>4</sup>.
|
31340894 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We divided 36 patients with schizophrenia who had undergone treatment mainly with risperidone into two groups: one with normal metabolizing activity of CYP2D6 (n = 15), and the other with lower activity of its variant, CYP2D6*10 (n = 21).
|
30870237 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genotyping of clinically relevant <i>CYP2D6</i> alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy.
|
31178724 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
|
31195002 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
|
29135105 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results are consistent with the relatively few other large, population-based studies conducted to date that have not observed an increased risk of adverse BC outcomes associated with CYP2D6 inhibition.
|
30542984 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
|
30843495 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.
|
30357449 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AD susceptibility gene cholesterol 25-hydroxylase (<i>CH25H</i>) is upregulated in the AD brain and is involved in the antiviral immune response.
|
29559905 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer.
|
29385237 |
2018 |